MetALD: How America's Obesity and Alcohol Crisis Is Fueling a Deadly Liver Disease

What Is MetALD and Why Is It Spreading in the U.S.?

While heavy and binge drinking is a global issue, the United States faces a unique liver health crisis. The country’s rising obesity and diabetes rates, paired with excessive alcohol consumption, are fueling a surge in a newly recognized liver disease: Metabolic dysfunction and alcohol-associated liver disease (MetALD).

Until recently, this condition lacked a formal name. Now, it has become a leading concern among U.S. doctors as more young people and women develop severe illness—or even die—from MetALD. Many cases may go undiagnosed because patients and even physicians often underestimate alcohol consumption.

Who Is at Risk for MetALD?

MetALD develops in individuals who have:

• Liver fat accumulation
• Metabolic risk factors such as obesity, prediabetes, diabetes, high blood pressure, or high cholesterol
• Alcohol consumption exceeding 10 drinks per week for women or 15 drinks per week for men

Since 1990, the number of Americans meeting these criteria has more than doubled, according to research. A JAMA Internal Medicine study found that nearly 1 in 10 U.S. adults report both heavy drinking and obesity.

How Common Is MetALD—and Who’s Most Affected?

MetALD is now nearly twice as prevalent as alcohol-associated liver disease alone. The disease disproportionately impacts younger adults, with those aged 26 to 34 showing the highest rates of overlapping alcohol use disorder and obesity, based on national survey data.

“If you drink alcohol, you are going to accumulate fat in the liver,” warned Dr. Juan Pablo Arab, a liver researcher and transplant hepatologist. “But what happens if you already have obesity and insulin resistance, and you already have fat in your liver?”

This combination creates a dangerous scenario. Over one-third of Americans have concerning levels of liver fat, a condition known as steatotic liver disease. Additionally, a third of adults meet the criteria for MASLD (metabolic dysfunction-associated steatotic liver disease), previously called non-alcoholic fatty liver disease (NAFLD).

Why the Urgency?

Experts warn that MetALD is a silent epidemic. Many patients do not recognize their drinking habits as excessive, and physicians may overlook the condition until it progresses to severe liver damage. The overlap of metabolic disorders and alcohol use accelerates liver disease, making early detection and intervention critical.

As obesity and diabetes rates continue to climb alongside alcohol consumption, the burden of MetALD is expected to grow, posing a significant public health challenge for the U.S.